Swiss pharmaceutical giant Novartis has agreed to buy London-based biotech Myricx Bio for up to $1.5bn (£1.1bn) as global ...

Pharvaris stock jumped early Monday after the FDA agreed to review the company's experimental treatment for a serious ...

They have at least one thing in common: An exciting pipeline.

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, ...

Call AI in biotech hype at your peril. There are real reasons that pharmaceutical companies are embracing this technology ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...